(Q82582041)

English

Exenatide

scientific article published on 01 March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

Exenatide (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Grant M Bray

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 March 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

American Journal of Health-System Pharmacy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

63

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

411-418

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Relationships of upper gastrointestinal motor and sensory function with glycemic control

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Incretin mimetics as emerging treatments for type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050459

31 March 2020

Identifiers

10.2146/AJHP050459

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16484515%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82582041&oldid=1366090995"